HC Wainwright Issues Positive Forecast for Celcuity Earnings

Celcuity, Inc. (NASDAQ:CELC) – Stock analysts at HC Wainwright increased their FY2027 EPS estimates for Celcuity in a research report issued on Friday, March 27th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings of $0.81 per share for the year, up from their prior estimate of $0.65. The consensus estimate for Celcuity’s current full-year earnings is ($2.62) per share. HC Wainwright also issued estimates for Celcuity’s FY2029 earnings at $7.97 EPS.

Several other equities research analysts have also weighed in on CELC. Wall Street Zen raised Celcuity from a “sell” rating to a “hold” rating in a research report on Saturday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Celcuity in a research note on Wednesday, January 21st. Needham & Company LLC reissued a “buy” rating and set a $122.00 price objective on shares of Celcuity in a report on Thursday, March 26th. Wolfe Research restated an “outperform” rating and set a $110.00 price objective on shares of Celcuity in a research report on Thursday, March 12th. Finally, Stifel Nicolaus upped their target price on shares of Celcuity from $115.00 to $125.00 and gave the company a “buy” rating in a report on Thursday, March 26th. Eight analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $109.88.

Celcuity Trading Up 5.4%

NASDAQ:CELC opened at $114.14 on Monday. Celcuity has a 1 year low of $7.57 and a 1 year high of $120.32. The stock has a market cap of $5.52 billion, a P/E ratio of -30.12 and a beta of 0.38. The company has a debt-to-equity ratio of 3.20, a quick ratio of 10.55 and a current ratio of 10.55. The stock has a 50-day simple moving average of $109.69 and a 200-day simple moving average of $91.97.

Celcuity (NASDAQ:CELC) last posted its earnings results on Wednesday, March 25th. The company reported ($0.97) EPS for the quarter, beating the consensus estimate of ($1.06) by $0.09.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. NEA Management Company LLC boosted its holdings in shares of Celcuity by 64.9% in the fourth quarter. NEA Management Company LLC now owns 3,535,561 shares of the company’s stock valued at $352,637,000 after acquiring an additional 1,391,300 shares during the period. Avoro Capital Advisors LLC acquired a new position in shares of Celcuity in the 4th quarter valued at $310,302,000. Soleus Capital Management L.P. increased its holdings in shares of Celcuity by 17.0% in the 2nd quarter. Soleus Capital Management L.P. now owns 3,011,818 shares of the company’s stock valued at $40,208,000 after acquiring an additional 437,696 shares during the period. Vanguard Group Inc. raised its position in Celcuity by 10.7% in the 4th quarter. Vanguard Group Inc. now owns 2,279,433 shares of the company’s stock valued at $227,351,000 after purchasing an additional 220,386 shares during the last quarter. Finally, State Street Corp raised its position in Celcuity by 126.6% in the 4th quarter. State Street Corp now owns 1,637,687 shares of the company’s stock valued at $163,343,000 after purchasing an additional 914,887 shares during the last quarter. Institutional investors and hedge funds own 63.33% of the company’s stock.

Insider Buying and Selling at Celcuity

In related news, Director David Dalvey sold 20,000 shares of the company’s stock in a transaction dated Tuesday, January 27th. The stock was sold at an average price of $120.03, for a total value of $2,400,600.00. Following the completion of the sale, the director directly owned 90,000 shares of the company’s stock, valued at $10,802,700. This represents a 18.18% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 15.78% of the company’s stock.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.